welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Dyne Therapeutics Announces Equity Investment from CureDuchenne Ventures to Support Pioneering Approach to Restoring Muscle Health in DMD
WALTHAM, Mass., March 31, 2020 – Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced an equity
investment from CureDuchenne Ventures. The funding will support Dyne’s development of precision therapeutics designed to restore muscle health in people living with Duchenne muscular dystrophy (DMD).
“Dyne’s partnership with CureDuchenne underscores our deep commitment and our sense of urgency as we work to bring life-transforming therapies to patients living with DMD and other serious muscle disorders. We appreciate the collaboration with and investment from CureDuchenne Ventures, which will help us advance our novel approach to targeting the genetic basis of DMD, with the goal of halting disease progression and restoring muscle health,” said Joshua Brumm, Dyne’s president and chief executive officer. “We look forward to continuing to collaborate with CureDuchenne and all of our partners in the Duchenne community. Together, we will improve the lives of those impacted by this devastating disease.”
rareRelated
-
Nationwide Children’s Hospital Begins New First-in-Human Clinical Study for DMD Using a Novel Gene Therapy Approac...CureDuchenne is very proud that Dr. Kevi...
-
Sarepta Therapeutics Announces Positive Safety and Efficacy Data from the SRP-9001 Micro-Dystrophin Gene Therapy Tri...06/15/20 11:00 AM EDT -- Results at...
-
Wave Life Sciences Announces Positive Phase 1 Results for WVE-210201 in Duchenne Muscular Dystrophy (DMD)WVE-210201 safety and tolerability profi...
-
Catabasis Connection Newsletter July 2020In this month’s newsletter, Catabasis ...
-
Solid Biosciences Provides Data Update from SGT-001 Development ProgramSolid Biosciences Inc. (Nasdaq: SLDB) to...
-
Neurodevelopmental Needs in Young Boys with Duchenne Muscular Dystrophy (DMD): Observations from the Cooperative Int...Introduction: Duchenne muscular dystroph...
-
Pfizer’s new Phase 1b Results of Gene Therapy in Ambulatory Boys With Duchenne Muscular Dystrophy (DMD) Support Ad...Friday, May 15, 2020 - 8:00 AM EDT Pfiz...
